Filter By Category
Archives
Share on -
ANITOCABTAGENE AUTOLEUCEL
Generic Name: ANITOCABTAGENE AUTOLEUCEL
ABSTRACT -
Anitocabtagene autoleucel is an investigational autologous BCMA-directed chimeric antigen receptor T-cell therapy being studied for relapsed or refractory multiple myeloma. The patient's T cells are engineered to recognize BCMA-expressing plasma cells and mediate targeted cytotoxic activity.
DOSAGE -
- Dosage should be determined only by a qualified cellular-therapy specialist.
- Treatment is individualized from an autologous cell product and administered after lymphodepleting chemotherapy according to trial protocol.
- A single cellular infusion is typical in CAR-T protocols, but cell dose is product- and protocol-specific.
- Patients require specialized monitoring for cytokine release syndrome and neurotoxicity.
SIDE EFFECTS–
- Possible side effects include:
- Cytokine release syndrome
- Immune effector cell-associated neurotoxicity syndrome
- Prolonged cytopenias
- Infections
- Fever
- Fatigue
- Hypogammaglobulinemia
- Tumor lysis syndrome
- Infusion reactions
ALLRGIC REACTIONS–
- Possible allergic reaction symptoms include:
- Infusion-related hypersensitivity
- Rash
- Urticaria
- Bronchospasm
- Anaphylaxis symptoms
- Important: Patients who develop an allergic reaction to Anitocabtagene Autoleucel should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
- Immunosuppressive medicines may reduce CAR-T activity but may be required for toxicity management.
- Live vaccines should be avoided until immune recovery.
- Other myelosuppressive therapies can worsen cytopenias.
- Corticosteroids and cytokine blockers must follow toxicity protocols.
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Administer only in certified or highly specialized centers.
- Monitor for fever, hypotension, hypoxia, neurologic changes, infection, and cytopenias.
- Patients should remain near the treatment center during the high-risk period.
- Do not drive or perform hazardous activities during neurotoxicity risk period.
WARNINGS –
- CRS and neurotoxicity can be life-threatening.
- Urgent medical evaluation is needed for fever, confusion, seizure, weakness, or breathing difficulty.
- Investigational product; use only under approved protocol or authorization.
- Keep out of reach of children.
Share on -
. Developed by